Publication | Closed Access

The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis

InflammationMetabolic SyndromeMolecular PharmacologyLipid DisorderBiochemistryImproves DyslipidemiaMedicinePhysiologyReverse Cholesterol TransportVascular BiologyLipoprotein MetabolismPharmacologyAtherosclerosisDyslipidemiaHealth Sciences